Curcumin and recovery time in COVID-19 patients
20th Jan, 2021

 Curcumin and COVID-19


Curcumin improves recovery time in COVID-19 patients


Published in Phytotherapy Research, the findings of a recent clinical trial indicate that curcumin may improve the recovery time of hospitalised patients with mild-to-moderate coronavirus disease-19 (COVID-19) (1). 

In the open-label non-randomised clinical trial, 41 inpatients diagnosed with mild-to-moderate COVID-19 based on PCR test, lung CT, and clinical signs and symptoms were assigned to either a nano-curcumin group (n=21) or a control group (n=20). The nano-curcumin group received two capsules twice daily containing 40 mg curcuminoids as nanomicelles for 2 weeks. Patients in both groups received standard care, with no significant difference between the nano-curcumin and control group regarding standard treatment (1). 

Compared to the control group, the nano-curcumin group had faster resolution of symptoms including fever and chills, cough, tachypnoea, and myalgia, and significantly higher lymphocyte counts after 1 week and at discharge. 

Atrial O2 saturation (SaO2) was significantly higher in the nano-curcumin group after 2, 4, 7, and 14 days of follow-up. The length of supplementation oxygen use and hospitalisation was significantly shorter than the control group. 

Nearly half of the patients (47.62%) in the nano-curcumin group experienced complete recovery, including full symptom resolution and normalisation of CRP, SaO2 and lymphocyte count, compared to 15% in the control group. 

In the nano-curcumin group, no patients experienced a deterioration of infection during the 2-week follow-up period, but 40% of the control group did. No significant adverse reactions were reported in the nano-curcumin group (1). 

As an anti-inflammatory, curcumin has potent inhibitory effects on NF-κB, and several proinflammatory cytokines, including interleukins IL-1, IL-6, and TNF-α. These anti-inflammatory effects may mitigate the pathophysiological and clinical features of COVID-19 (2,3,4). Furthermore, curcumin has antioxidant, immunomodulatory, anticoagulant, and anti-viral effects (2,3,5). 

Acute respiratory distress syndrome (ARDS) causes pulmonary fibrosis and is the leading cause of COVID-19 mortality, mostly due to cytokine storm induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (6,7). Experimental studies indicate that curcumin can modulate the inflammatory response in viral-induced acute respiratory distress syndrome and suppress pulmonary inflammation, fibrosis, and oedema (8,9).  

Curcumin has demonstrated activity against numerous viruses, including influenza and other coronaviruses, by interfering with viral replication cycle, penetration, and cellular signalling (5,10). Recently, curcumin has been shown in silico studies (computer simulations) to prevent the entry of the SARS-CoV-2 into cells, by binding to viral proteins and viral attachment sites of ACE2 receptor, as well as inhibiting viral replication (11,12,13).

The current study is the first human clinical trial to evaluate curcumin efficacy and safety in COVID-19 infection. Results suggest curcumin can significantly improve recovery time from mild-to-moderate COVID-19 infection. Further high-quality, double-blind, randomised controlled trials with larger sample size are required to assess the study's clinical significance, particularly in patients with a more severe form of infection. 

1Saber‐Moghaddam N, Salari S, Hejazi S, Amini M, Taherzadeh Z, Eslami S, Rezayat SM, Jaafari MR, Elyasi S. Oral nano‐curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease‐19 patients: An open label nonrandomized clinical trial. Phytotherapy Research. 2021 Jan 3.
2Zahedipour F, Hosseini SA, Sathyapalan T, Majeed M, Jamialahmadi T, Al-Rasadi K, et al. Potential effects of curcumin in the treatment of COVID-19 infection. Phytotherapy Research 2020 May 19;34(11):2911–20.
3Soni VK, Mehta A, Ratre YK, Tiwari AK, Amit A, Singh RP, Sonkar SC, Chaturvedi N, Shukla D, Vishvakarma NK. Curcumin, a traditional spice component, can hold the promise against COVID-19?. European Journal of Pharmacology. 2020 Nov 5;886:173551.
4Liu Z, Ying Y. The Inhibitory Effect of Curcumin on Virus-Induced Cytokine Storm and Its Potential Use in the Associated Severe Pneumonia. Front Cell Dev Biol. 2020 Jun; 8:1–10.
5Zorofchian Moghadamtousi S, Abdul Kadir H, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. BioMed research international. 2014 Oct;186864.
6Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, HLH Across Speciality Collaboration. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020 Mar 28;395(10229):1033-34.
7Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine. 2020 May;46(5):846-8.
8Avasarala S, Zhang F, Liu G, Wang R, London SD, London L. Curcumin modulates the inflammatory response and inhibits subsequent fibrosis in a mouse model of viral-induced acute respiratory distress syndrome. PloS one. 2013 Feb 20;8(2):e57285.
9Chen H, Yang R, Tang Y, Xu J, Feng Y, Liu S, Zhang S, Hou L. Effects of curcumin on pulmonary fibrosis and functions of paraquat-challenged rats. Zhonghua wei zhong bing ji jiu yi xue. 2017 Nov 1;29(11):973-6.
10Mathew D, Hsu WL. Antiviral potential of curcumin. Journal of functional foods. 2018 Jan 1;40:692-9.
11Huynh T, Wang H, Luan B. In Silico Exploration of Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease. The journal of physical chemistry letters. 2020 May 14; 11:4413-20.
12Shanmugarajan D, Prabitha P, Kumar BP, Suresh B. Curcumin to inhibit binding of spike glycoprotein to ACE2 receptors: computational modelling, simulations, and ADMET studies to explore curcuminoids against novel SARS-CoV-2 targets. RSC Advances. 2020 Aug;10(52):31385-99.
13Emirik M. Potential therapeutic effect of turmeric contents against SARS-CoV-2 compared with experimental COVID-19 therapies: In silico study. Journal of Biomolecular Structure and Dynamics. 2020 Oct 19:1-4